Understand the source comparison
Peptides vs Rapamycin Longevity Research: Direct Comparison
Primary target mTORC1 kinase inhibition Telomerase activation (proposed) Thymic peptide receptor modulation Toll-like receptor signaling Rapamycin has the clearest single-target mechanism validated across species Lifespan extension (mice) 9–14% median increase
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary target
- mTORC1 kinase inhibition
- Telomerase activation (proposed)
- Thymic peptide receptor modulation
- Toll-like receptor signaling
- Rapamycin has the clearest single-target mechanism validated across species
- Lifespan extension (mice)
- 9–14% median increase (ITP studies)
- 12.3% in elderly rats (single lab)
- No survival data published
- Only rapamycin shows reproducible survival gains across independent labs
- Human clinical trials
- Phase I/II (PEARL trial: immune function)
- Small Russian trials (n<100, no FDA review)
- Phase II (immune restoration, USSR-era)
- Phase III (hepatitis, approved in 35 countries)
- Thymosin alpha-1 has the most robust human safety data; rapamycin has emerging longevity-focused trials
- Autophagy induction
- Strong (2.8× LC3-II increase)
- Minimal (not primary mechanism)
- Minimal
- Autophagy activation is unique to rapamycin. Peptides work through different pathways
- Immunosuppression risk
- Dose-dependent (high at >5mg daily)
- Minimal reported
- Minimal (immune-modulating, not suppressive)
- Rapamycin requires careful dosing to avoid infections; peptides carry lower immune risk
- Regulatory status (US)
- FDA-approved (Sirolimus, transplant rejection)
- Not approved (research compound)
- Not approved
- Not FDA-approved (approved elsewhere)
- Rapamycin is the only compound with formal FDA approval, though not for longevity